Asset Details
Do you wish to reserve the book?
Successful treatment of attention-deficit/hyperactivity disorder accompanying to alkaptonuria with methylphenidate and risperidone
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Successful treatment of attention-deficit/hyperactivity disorder accompanying to alkaptonuria with methylphenidate and risperidone
Do you wish to request the book?
Successful treatment of attention-deficit/hyperactivity disorder accompanying to alkaptonuria with methylphenidate and risperidone
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Successful treatment of attention-deficit/hyperactivity disorder accompanying to alkaptonuria with methylphenidate and risperidone
2019
Overview
Alkaptonuria (AKU) is a rare metabolic disorder resulting from deficiency of homogentisic acid (HGA) oxidase involved in the metabolism of tyrosine. Dark discolouration of urine, ochronosis at cartilage and connective tissues, arthritis at the third of fourth decade of life, cardiac valve deficits, renal stone disease, spontaneous tendon rupture, and liver involvement may be seen in alkaptonuria. It was reported that HGA oxidase gene was expressed in human cerebral tissue and neuronal cells in AKU with multi-systemic organ involvement. HGA accumulation has been implied and neurological problems and brain damage. To the best of our knowledge, there is no study or case report about psychiatric comorbidities in patients with AKU, although comorbid psychiatric disorders such as mental retardation, attention- deficit/hyperactivity disorder (ADHD), impulse control disorder or conduct disorder can be seen in some metabolic diseases such as mucopolysaccharidosis, Wilson’s disease, or phenylketonuria. Here, we presented a paediatric AKU patient with comorbid ADHD, oppositional defiant/conduct disorder (ODD/CD), and borderline intellectual functioning who was successfully treated with extended-release methylphenidate (OROS-MPH) and risperidone. It was observed that these agents caused no worsening in AKU and that they were well-tolerated without adverse effects. However, there is a need for further studies investigating the safe use of OROS-MPH and risperidone in patients with AKU.
Publisher
Aves Yayincilik Ltd. STI,Turkish Association for Psychopharmacology,Mesut Çetin
We currently cannot retrieve any items related to this title. Kindly check back at a later time.